JP7757345B2 - ミガラスタットの薬物動態を改善する方法 - Google Patents

ミガラスタットの薬物動態を改善する方法

Info

Publication number
JP7757345B2
JP7757345B2 JP2023090210A JP2023090210A JP7757345B2 JP 7757345 B2 JP7757345 B2 JP 7757345B2 JP 2023090210 A JP2023090210 A JP 2023090210A JP 2023090210 A JP2023090210 A JP 2023090210A JP 7757345 B2 JP7757345 B2 JP 7757345B2
Authority
JP
Japan
Prior art keywords
migalastat
salt
patient
formulation
caffeine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023090210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024084670A (ja
JP2024084670A5 (enExample
Inventor
フランクリン ジョンソン，
Original Assignee
アミカス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミカス セラピューティックス インコーポレイテッド filed Critical アミカス セラピューティックス インコーポレイテッド
Publication of JP2024084670A publication Critical patent/JP2024084670A/ja
Publication of JP2024084670A5 publication Critical patent/JP2024084670A5/ja
Application granted granted Critical
Publication of JP7757345B2 publication Critical patent/JP7757345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023090210A 2022-12-13 2023-05-31 ミガラスタットの薬物動態を改善する方法 Active JP7757345B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263432235P 2022-12-13 2022-12-13
US63/432,235 2022-12-13
US18/315,928 US20240197706A1 (en) 2022-12-13 2023-05-11 Methods of improving the pharmacokinetics of migalastat
US18/315,928 2023-05-11

Publications (3)

Publication Number Publication Date
JP2024084670A JP2024084670A (ja) 2024-06-25
JP2024084670A5 JP2024084670A5 (enExample) 2025-04-23
JP7757345B2 true JP7757345B2 (ja) 2025-10-21

Family

ID=86646511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023090210A Active JP7757345B2 (ja) 2022-12-13 2023-05-31 ミガラスタットの薬物動態を改善する方法

Country Status (13)

Country Link
US (1) US20240197706A1 (enExample)
EP (1) EP4385509B1 (enExample)
JP (1) JP7757345B2 (enExample)
KR (1) KR20240094973A (enExample)
AU (1) AU2023396459A1 (enExample)
CA (1) CA3201512A1 (enExample)
CL (1) CL2025001743A1 (enExample)
CO (1) CO2025009079A2 (enExample)
DE (1) DE202023003007U1 (enExample)
IL (1) IL321404A (enExample)
MX (1) MX2025006897A (enExample)
TW (1) TW202423436A (enExample)
WO (1) WO2024129220A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528901A (ja) 2011-03-11 2014-10-30 アミカス セラピューティックス インコーポレイテッド ファブリー病の治療用投薬レジメン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
LT3470077T (lt) 2008-02-12 2021-02-25 Amicus Therapeutics, Inc. Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas
JP2024542023A (ja) * 2021-11-03 2024-11-13 サンガモ セラピューティクス，インコーポレイテッド ファブリー病の治療のためのウイルスベクター構築物の使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528901A (ja) 2011-03-11 2014-10-30 アミカス セラピューティックス インコーポレイテッド ファブリー病の治療用投薬レジメン

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Galafold: EPAR - Product Information"，[online]，[検索日 2025.04.18]，2021年02月11日，<URL: https://www.ema.europa.eu/en/documents/product-information/galafold-epar-product-information_en.pdf>
Clinical Pharmacology in Drug Development，2015年，Vol.4, No.3，pp.193-202
Pharmacological Reviews，1999年，Vol.51, No.1，pp.83-133
医療用医薬品：ガラフォルド，[online]，2021年09月14日，[検索日 2025.04.18]，<URL: https://web.archive.org/web/20210914154656/https://www.kegg.jp/medicus-bin/japic_med?japic_code=00067442>

Also Published As

Publication number Publication date
JP2024084670A (ja) 2024-06-25
CA3201512A1 (en) 2024-06-13
CL2025001743A1 (es) 2025-10-03
KR20240094973A (ko) 2024-06-25
EP4385509B1 (en) 2025-09-03
IL321404A (en) 2025-08-01
DE202023003007U1 (de) 2025-07-21
WO2024129220A1 (en) 2024-06-20
MX2025006897A (es) 2025-07-01
TW202423436A (zh) 2024-06-16
EP4385509A1 (en) 2024-06-19
US20240197706A1 (en) 2024-06-20
AU2023396459A1 (en) 2025-06-26
CO2025009079A2 (es) 2025-09-29

Similar Documents

Publication Publication Date Title
JP7677910B2 (ja) 腎機能障害を有する患者のファブリー病を治療する方法
EP3840753B1 (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
WO2019046244A1 (en) METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
EP4114390B1 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
JP7680356B2 (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP7757345B2 (ja) ミガラスタットの薬物動態を改善する方法
WO2023288210A1 (en) Methods of treating fabry disease in pediatric patients
HK40110919A (en) Migalastat formulations having improved pharmacokinetics
CN118488839A (zh) 改善米加司他的药代动力学的方法
HK40104441A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40105450A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104069A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104071A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104764A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40122460A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125B (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125A (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250415

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251008

R150 Certificate of patent or registration of utility model

Ref document number: 7757345

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150